Back to results
US 10,377,810 B2Granted
Soluble CD80 as a therapeutic to reverse immune suppression in cancer patients
AssigneeUniversity of Maryland, Baltimore County
InventorSuzanne Ostrand-Rosenberg
Life of this patent
Estimating the term…
Abstract
The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.
Claims4
A mutated CD80 peptide consisting of the amino acid sequence of SEQ ID NO:
- 15.
A chimeric peptide comprising a mutated CD80 amino acid sequence and a Fc IgG1 amino acid sequence, wherein the mutated CD80 amino acid sequence consists of the amino acid sequence of SEQ ID NO:
- 15.
Dependencies are inferred from the claim text.